Last reviewed · How we verify
NCT05189171: MODEL-CRC
MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer
trial testing MicroOrganoSphere (MOS) drug screen in Colorectal Neoplasms in 46 participants. Completed in 18 March 2024.
3 November 2023
Quick facts
| Lead sponsor | Xilis, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 46 |
| Start date | 25 October 2022 |
| Primary completion | 3 November 2023 |
| Estimated completion | 18 March 2024 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- MicroOrganoSphere (MOS) drug screen
Conditions studied
- Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Sponsor
Xilis, Inc.
Who can join
18 and older, any sex, with Colorectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to determine the feasibility of generating sufficient MicroOrganoSpheres (MOS) from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and completing a drug screen against patient-derived MOS using standard of care drugs used in the treatment of colorectal cancer (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab) in ≤ 14 days.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Patient-derived micro-organospheres enable clinical precision oncology.
Ding S, Hsu C, Wang Z, Natesh NR, et al · · 2022 · cited 148× · PMID 35508177 · DOI 10.1016/j.stem.2022.04.006
Verify or expand the search:
- PubMed search for NCT05189171
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Neoplasms
Currently open trials in the same condition.
- NCT06983639 — Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance · NA · recruiting
- NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
- NCT07239479 — DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy · NA · recruiting
- NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
- NCT07257653 — The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05189171 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xilis, Inc.
- Last refreshed: 28 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05189171.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing